

Table 2. a) Sequential changes of serum IGF-1value after GH treatment

Sex	Age	Pre GH treatment	6M	1Y	2Y	3Y	4Y	5Y	6Y	7Y
Male	>60Y	94.8±44.7 (N=29)	176±61.1* (N=29)	189±88.8* (N=25)	178±43.1* (N=18)	161±32.4* (N=15)	158±29.6* (N=11)	161±22.8* (N=6)	162±22.6* (N=4)	174±19.1 (N=2)
	≤60Y	85±48.2 (N=20)	157±39.7* (N=20)	148±46.8* (N=19)	139±41.3* (N=17)	130±35.5* (N=15)	121±33.2* (N=9)	139±28.7 (N=5)	119±16.2 (N=3)	156±19.1 (N=2)
Female	>60Y	91±45.9 (N=14)	161±50.3* (N=12)	156±64.7* (N=12)	148±35.3* (N=9)	127±42.6* (N=9)	134±41.9 (N=7)	150±30.9 (N=3)	153±32.5 (N=2)	N=1
	≤60Y	86.8±60.7 (N=21)	149±64.5* (N=21)	156±44.5* (N=19)	161±59* (N=14)	154±26.8* (N=12)	163±40.5* (N=10)	167±21.9 (N=3)	185±26.3 (N=2)	N=1

*: significant; (p<0.05)

Data are compared with pre GH treatment and 6M, 1Y, 2Y, 3Y, 4Y, 5Y, 6Y, 7Y after GH treatment.

IGF-1 value; Mean ±SD; N: number of patients

Table 2. b) Sequential changes of IGF-1 SD score after GH treatment

Sex	Age	Pre GH treatment	6M	1Y	2Y	3Y	4Y	5Y
Male	>60Y	-2.32±1.82 (N=29)	0.08±1.51* (N=29)	0.3±1.71* (N=25)	0.48±1.07* (N=18)	0.2±0.79* (N=15)	0.18±0.69* (N=11)	0.25±0.63* (N=6)
	≤60Y	-1.84±1.81 (N=20)	0.56±1.02* (N=20)	0.27±1.1* (N=19)	0.11±1.14* (N=17)	-0.11±0.92* (N=15)	-0.33±1.01* (N=9)	0.28±0.56 (N=5)
Female	>60Y	-2.43±1.95 (N=13)	0.14±0.86* (N=12)	-0.33±2.37* (N=12)	-0.38±1.15* (N=9)	-1±1.12* (N=9)	-0.51±1.23* (N=7)	-0.5±0.56 (N=3)
	≤60Y	-1.5±2.29 (N=21)	0.74±1.75* (N=21)	1.19±1.14* (N=19)	1.24±1.27* (N=14)	1.16±0.61* (N=12)	1.35±0.89* (N=10)	1.37±0.25 (N=3)

*: significant (p<0.05);

Data are compared with pre GH treatment and 6M, 1Y, 2Y, 3Y, 4Y, 5Y, 6Y, 7Y after GH treatment.

IGF-1SD score; Mean ±SD; N: number of patients.